Emergent Biosolutions INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.7Mgeneral payments (2019-2025)
$958Kresearch payments (2019-2025)
941clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| James Mccarty | Madera, CA | Pediatric Infectious Diseases | $789,705.22 |
| Mark Gold | Gainesville, FL | Addiction Medicine (Internal Medicine) | $290,724.84 |
| Timothy Babinchak | Phoenixville, PA | Infectious Disease | $134,200.00 |
| Christopher Belcher | Carmel, IN | Pediatric Infectious Diseases | $57,854.22 |
| John Niederhuber | Falls Church, VA | Surgical Oncology | $48,000.00 |
| Sean Bennett | Charlottesville, VA | $28,900.00 | |
| Bill Mccarberg | San Diego, CA | Family Medicine | $27,877.47 |
| Steven Stanos | Seattle, WA | Pain Medicine (Physical Medicine & Rehabilitation) | $27,484.16 |
| Jennifer Caudle | Sewell, NJ | Family Medicine | $20,000.00 |
| Kim Erlich | Burlingame, CA | Infectious Disease | $17,730.49 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.